Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 2/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28360321 | 0.84 | ALDH1A1 (0.58) | ALDH1A1CYP1A1CYP1B1 | |
| SCHEMBL15958517 | 0.83 | ALDH1A1 (0.42) | ALDH1A1GRM5MGLLHPGDSKDM1A | |
| SCHEMBL202404 | 0.82 | ALDH1A1 (0.61) | ALDH1A1GRM5HPGDSKDM1APGR | |
| SCHEMBL6682154 | 0.81 | ALDH1A1 (0.41) | ALDH1A1GRM5MGLLHPGDSKDM1A | |
| SCHEMBL3633607 | 0.81 | APP (0.48) | — | |
| SCHEMBL29373993 | 0.81 | APP (0.48) | — | |
| SCHEMBL16961695 | 0.80 | ALDH1A1 (0.39) | ALDH1A1GRM5MGLLHPGDSKDM1A | |
| SCHEMBL509576 | 0.80 | ALDH1A1 (0.58) | ALDH1A1GRM5HPGDSKDM1APGR | |
| SCHEMBL1890750 | 0.80 | VCAM1 (0.38) | EPAS1 | |
| SCHEMBL21164288 | 0.79 | MGLL (0.38) | ALDH1A1GRM5MGLLHPGDSKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063064-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-11-22 | — | — | US | disclosed |
| US-7906540-B2 | Antivirals for HIV and AIDS; compounds are 2-1,2,4-triazolin-5-ones, substituted with aryl(oxy)methyl or benzylamino at position 3; use in combination with antivirals; treating drug resistance infections | ROCHE PALO ALTO LLC (US) | 2011-03-15 | — | — | US | disclosed |
| US-20110059975-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | KENNEDY-SMITH JOSHUA | 2011-03-10 | — | — | US | disclosed |
| EP-2142520-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | disclosed |
| EP-2134711-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20080293664-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2008-11-27 | — | — | US | disclosed |
| WO-2008122534-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008119662-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| US-20080249151-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293664-A1 | Non-nucleoside reverse transcriptase inhibitors | XDH, REV1, RTF1 | EPAS1 2720/4885ALDH1A1 529/4885GRM5 4392/4885 |
| US-20110059975-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | RPIA, ADORA2B, NQO2 | EPAS1 3701/4885ALDH1A1 942/4885GRM5 2130/4885 |
| US-20080249151-A1 | Non-nucleoside reverse transcriptase inhibitors | QTRT1, RTF1, REV1 | EPAS1 3074/4885ALDH1A1 442/4885GRM5 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.